Literature DB >> 18624918

Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.

Luigi Zecca1, Luigi Casella, Alberto Albertini, Chiara Bellei, Fabio A Zucca, Mireille Engelen, Andrzej Zadlo, Grzegorz Szewczyk, Mariusz Zareba, Tadeusz Sarna.   

Abstract

In Parkinson's disease (PD), dopamine neurons containing neuromelanin selectively degenerate. Neuromelanin binds iron and accumulates in aging. Iron accumulates in reactive form during aging, PD, and is involved in neurodegeneration. It is not clear how the interaction of neuromelanin and iron can be protective or toxic by modulating redox processes. Here, we investigated the interaction of neuromelanin from human substantia nigra with iron in the presence of ascorbic acid, dopamine, and hydrogen peroxide. We observed that neuromelanin blocks hydroxyl radical production by Fenton's reaction, in a dose-dependent manner. Neuromelanin also inhibited the iron-mediated oxidation of ascorbic acid, thus sparing this major antioxidant molecule in brain. The protective effect of neuromelanin on ascorbate oxidation occurs even in conditions of iron overload into neuromelanin. The blockade of iron into a stable iron-neuromelanin complex prevents dopamine oxidation, inhibiting the formation of neurotoxic dopamine quinones. The above processes occur intraneuronally in aging and PD, thus showing that neuromelanin is neuroprotective. The iron-neuromelanin complex is completely decomposed by hydrogen peroxide and its degradation rate increases with the amount of iron bound to neuromelanin. This occurs in PD when extraneuronal iron-neuromelanin is phagocytosed by microglia and iron-neuromelanin degradation releases reactive/toxic iron.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18624918     DOI: 10.1111/j.1471-4159.2008.05541.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  77 in total

1.  Clinical utility of visualisation of nigrosome-1 in patients with Parkinson's disease.

Authors:  Albert Stezin; Rajini M Naduthota; Ragasudha Botta; Shriram Varadharajan; Abhishek Lenka; Jitender Saini; Ravi Yadav; Pramod Kumar Pal
Journal:  Eur Radiol       Date:  2017-08-04       Impact factor: 5.315

2.  The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.

Authors:  Raymond J Bergeron; Neelam Bharti; Jan Wiegand; James S McManis; Shailendra Singh; Khalil A Abboud
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

Review 3.  Neuromelanin of the human substantia nigra: an update.

Authors:  Fabio A Zucca; Emy Basso; Francesca A Cupaioli; Emanuele Ferrari; David Sulzer; Luigi Casella; Luigi Zecca
Journal:  Neurotox Res       Date:  2013-10-24       Impact factor: 3.911

4.  A reappraisal of Fe(III) adsorption by melanin.

Authors:  Rhiannon Lee Schroeder; Jacobus Petrus Gerber
Journal:  J Neural Transm (Vienna)       Date:  2014-05-21       Impact factor: 3.575

Review 5.  Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review.

Authors:  Sara Pietracupa; Antonio Martin-Bastida; Paola Piccini
Journal:  Neurol Sci       Date:  2017-09-02       Impact factor: 3.307

6.  Glutathione transferase mu 2 protects glioblastoma cells against aminochrome toxicity by preventing autophagy and lysosome dysfunction.

Authors:  Sandro Huenchuguala; Patricia Muñoz; Patricio Zavala; Mónica Villa; Carlos Cuevas; Ulises Ahumada; Rebecca Graumann; Beston F Nore; Eduardo Couve; Bengt Mannervik; Irmgard Paris; Juan Segura-Aguilar
Journal:  Autophagy       Date:  2014-01-14       Impact factor: 16.016

7.  T1rho and T2rho MRI in the evaluation of Parkinson's disease.

Authors:  I Nestrasil; S Michaeli; T Liimatainen; C E Rydeen; C M Kotz; J P Nixon; T Hanson; Paul J Tuite
Journal:  J Neurol       Date:  2010-01-08       Impact factor: 4.849

Review 8.  Iron accumulation in Parkinson's disease.

Authors:  Hideki Mochizuki; Toru Yasuda
Journal:  J Neural Transm (Vienna)       Date:  2012-10-16       Impact factor: 3.575

9.  Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.

Authors:  Raymond J Bergeron; Jan Wiegand; Neelam Bharti; James S McManis
Journal:  J Med Chem       Date:  2012-08-13       Impact factor: 7.446

10.  Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle.

Authors:  Kristen A Malkus; Elpida Tsika; Harry Ischiropoulos
Journal:  Mol Neurodegener       Date:  2009-06-05       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.